Hematology Oncology Division, Internal Medicine Department, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Clin Lab Anal. 2021 Nov;35(11):e24046. doi: 10.1002/jcla.24046. Epub 2021 Oct 9.
Few studies have investigated the alterations in the T and B cell counts and related subgroups in pulmonary infections especially COVID-19. Here, we aimed to evaluate total T and B lymphocytes and T cell subgroup counts to find the possible correlation between number of these cells and severity and mortality in COVID-19 patients.
This study was performed on 40 patients with severe COVID-19 infection confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and chest HRCT in August 2020. By the time of admission, T lymphocytes profile in peripheral blood was investigated using multicolor flow cytometry. The total number of T lymphocytes, CD4+ T cells, CD8+ T cells, and B lymphocytes were calculated. Expression of CD2, CD3, CD5, and CD7 as pan T cell surface markers and expression of CD38 and HLA-DR as activated markers on T lymphocytes were also evaluated.
Nine patients (22.5%) died during the study and 16 patients (40%) were admitted to ICU. Deceased patients demonstrated lower amounts of T cell count and CD4+ T cell count (with a marginal difference (p = 0.07)) compared with survived patients at the time of admission. The chance of mortality was significantly higher for patients with CD7 loss (OR = 14.89). A marginally significant relationship was also indicated between CD4<200/ml and mortality (OR = 8.65), but no other significant relationships were observed between variables and ICU admission.
Altogether, CD7 loss on T lymphocytes and CD4+ T cell count below 200/ml revealed a significant relationship with mortality. Considering T lymphocytes and T cell subgroup count could have a predictive value for patients suffering from COVID-19.
很少有研究调查过肺部感染,特别是 COVID-19 中 T 细胞和 B 细胞计数的变化以及相关亚群。在这里,我们旨在评估总 T 和 B 淋巴细胞以及 T 细胞亚群计数,以发现这些细胞数量与 COVID-19 患者严重程度和死亡率之间的可能相关性。
这项研究于 2020 年 8 月对 40 名经逆转录-聚合酶链反应(RT-PCR)和胸部高分辨率 CT(HRCT)确诊为严重 COVID-19 感染的患者进行了研究。在入院时,使用多色流式细胞术检查外周血中的 T 淋巴细胞谱。计算总 T 淋巴细胞数、CD4+T 细胞数、CD8+T 细胞数和 B 淋巴细胞数。还评估了 T 淋巴细胞上的 pan T 细胞表面标志物 CD2、CD3、CD5 和 CD7 的表达以及激活标志物 CD38 和 HLA-DR 的表达。
研究期间有 9 名患者(22.5%)死亡,16 名患者(40%)入住 ICU。与存活患者相比,死亡患者在入院时的 T 细胞计数和 CD4+T 细胞计数较低(具有边缘差异(p=0.07))。CD7 缺失患者的死亡率明显更高(OR=14.89)。CD4<200/ml 与死亡率之间也存在边际显著关系(OR=8.65),但其他变量与 ICU 入院之间没有观察到显著关系。
总之,T 淋巴细胞上的 CD7 缺失和 CD4+T 细胞计数低于 200/ml 与死亡率显著相关。考虑到 T 淋巴细胞和 T 细胞亚群计数可能对 COVID-19 患者具有预测价值。